Product Images Divalproex Sodium
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 8 images provide visual information about the product associated with Divalproex Sodium NDC 70518-2674 by Remedyrepack Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
MM2 - Divalproex Sodium 500mg 70518 2674 01
Divalproex Sodium is a delayed-release medication with an NDC number of 70518-2674-01. The manufacturer is Sun Pharma located in Cranbury, NJ 08512. The medication should be stored between 20-26°C (63-77°F) with limited excursions to 15-30°C (59-86°F) as recommended by USP regulations. The package insert should be consulted for usage directions. It has also been repackaged by RemedyRepack Inc. located in Indiana, PA 15701. Keep the medication out of reach of children.*
Divalproex Sodium 500mg 70518 2674 02
Divalproex Sodium is a delayed-release tablet of 500 mg. The package contains 30 tablets and has an NDC number of 70518-2674-02. It is manufactured by Sun Pharma in Cranbury, N.J. 08512. It should be stored at 20-26°C (63-77°F), with excursions permitted to 15-30°C (59-86°F) in accordance with USP. The direction for use is available in the package insert. This package has been repackaged by RemedyRepack Inc., Indiana, PA 15701.*
Remedy_Label - Remedy Label
Divalproex Sodium is a type of medication that comes in a delayed-release 500 mg tablet format, with one bottle containing 100 tablets in total. The product is only available through a prescription (labeled RX ONLY). The packaging has a unique identifier number (NDC #: 70518-2674-00) and a recommended temperature storage range of 20-26°C (63-77°F), with exceptions permitted to 15-30°C (59-86°F). The medication is manufactured by Sun Pharma located in Cranbury, New Jersey 08512. The packaging also contains a warning to keep the medication out of the reach of children. For usage guidelines, individuals are instructed to refer to the attached package insert. The medication has been repackaged by RemedyRepack Inc. in Indiana, Pennsylvania 15701.*
spl-divalproex-figure-1 - spl divalproex figure 1
This text is a description of a figure with the label "Figure 1" and the titles "Study 1" and "Study 2". The figure displays the results of two studies, indicated by the abbreviations "YMRS" and "MRS". The treatments used in the studies are "PBO" and "DVPX". Without additional information, it is not possible to determine the nature or purpose of the studies or the significance of the results.*
spl-divalproex-figure-2 - spl divalproex figure 2
This appears to be a chart or graph showing the results of a study or experiment. The percentages on the left side indicate the rate of improvement or reduction in CPS (it is not clear what CPS stands for). The "Improvement", "No Change", and "Worsening" categories suggest that patients were evaluated for some sort of treatment or therapy. The chart includes a comparison between a drug called DVPX and a placebo. Without context or additional information it is difficult to provide a more detailed description or analysis.*
spl-divalproex-figure-3 - spl divalproex figure 3
spl-divalproex-figure-4 - spl divalproex figure 4
This is a figure presenting the mean 4-week migraine rates in two different studies comparing a placebo group to a DVPX group. Study 1 and Study 2 were performed and the results are displayed for both placebo and DVPX treatments.*
spl-divalproex-structure - spl divalproex structure
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.